The B-band O-antigen of the lipopolysaccharide found in the opportunistic pathogen Pseudomonas aeruginosa PAO1 (serotype O5) comprises a repeating trisaccharide unit that is critical for virulence and protection from host defense systems. One of the carbohydrates in this repeating unit, the rare diacetylated aminuronic acid derivative 2,3-diacetamido-2,3-dideoxy-β-D-mannuronic acid (ManNAc(3NAc)A), is thought to be produced by five enzymes (WbpA, WbpB, WbpE, WbpD and WbpI) in a stepwise manner starting from UDP-GlcNAc. Although the genes responsible for the biosynthesis of this sugar are known, only two of the five encoded proteins (WbpA and WbpI) have been thoroughly investigated. In this report, we describe the cloning, overexpression, purification and biochemical characterization of the three central enzymes in this pathway, WbpB, WbpE, and WbpD. Using a combination of capillary electrophoresis, RP-HPLC and NMR spectroscopy, we show that WbpB and WbpE are a dehydrogenase/aminotransferase pair that converts UDP-GlcNAcA to UDP-GlcNAc(3NH 2 )A in a coupled reaction via a unique NAD + recycling pathway. In addition, we confirm that WbpD catalyzes the acetylation of UDP-GlcNAc(3NH 2 )A to give UDP-GlcNAc (3NAc)A. Notably, WbpA, WbpB, WbpE, WbpD and WbpI can be combined in vitro to generate UDP-ManNAc(3NAc)A in a single reaction vessel, thereby providing supplies of this complex glycosyl donor for future studies of LPS assembly. This work completes the biochemical characterization of the enzymes in this pathway and provides novel targets for potential therapeutics to combat infections with drug resistant P. aeruginosa strains.The gram-negative pathogen Pseudomonas aeruginosa is a versatile organism responsible for infection in immunocompromised individuals (1). It is a major source of hospital-acquired pneumonia and bacteremia, causes severe inflammation and pulmonary failure in cystic fibrosis patients, and has emerged as a serious public health threat (2-5). Effective treatment of P. aeruginosa infection has proved challenging due to the strong inherent resistance of the organism to traditional antibiotics and the increasing emergence of multi-drug resistant strains (6-8). While several vaccines for P. aeruginosa have been described, none have thus far achieved clinical success (9). † This work was supported by a grant from National Institutes of Health (GM039334 to B.I.). *To whom correspondence should be addressed: Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139. Phone: (617) 253-1838; Fax: (617) 452-2419; Email: E-mail: imper@mit.edu. Table of constructs and oligonucleotides used in this study, as well as full 1 H, 13 C and COSY NMR spectra of UDP-GlcNAc(3NH 2 )A and UDP-GlcNAc(3NAc)A. This material is available free of charge via the Internet at http://pubs.acs.org.
SUPPORTING INFORMATION AVAILABLE
NIH Public Access
Author ManuscriptBiochemistry. Author manuscript; available in PMC 2010 June 16.
NIH-PA Author ManuscriptNIH-PA Author Manuscript
NIH-PA Author Manusc...